A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo Controlled Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia

Trial Profile

A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo Controlled Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs MGL-3196 (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Madrigal Pharmaceuticals
  • Most Recent Events

    • 13 Mar 2018 According to a Madrigal Pharmaceuticals media release, company expects to report full results later this year.
    • 08 Feb 2018 Primary endpoint [Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C)] has been met.
    • 08 Feb 2018 Results presented in a Madrigal Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top